Evidence for continued dose escalation of plerixafor for hematopoietic progenitor cell collections in sickle cell disease.

ABSTRACT: We present data from our study of plerixafor mobilization (NCT02193191) relevant to the question of whether further dose escalation of plerixafor can address inconsistent adequacy of CD34+ mobilization for gene therapy of sickle cell disease (SCD). We found that, in the same patient, higher plerixafor dosing was associated with higher fold increases in PB CD34+ count, but not necessarily higher absolute CD34+ counts. Variation in pre-apheresis absolute CD34+ counts was related to intra-individual variation in baseline PB CD34+ counts and inter-individual variation in responsiveness to plerixafor. Overall, our results support further studies of continued dose escalation of plerixafor for autologous HPC collection in SCD.

SUBMITTER: Boulad F 

PROVIDER: S-EPMC8338885 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature